Bayer's Nexavar misses another study endpoint, this time for breast cancer

Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication. Bayer announced today that the drug did not delay progression of patients with advanced breast cancer being studied in a Phase III trial, the primary endpoint for the study. Nexavar, which had sales last year of $1.06 billion, is approved for certain types of kidney cancer and for some patients with advanced thyroid cancer, but has been unable to work in some other areas. In March, Bayer reported that Nexavar had not met the endpoint in a study as an adjuvant therapy for liver cancer. In May of 2012, Nexavar failed to improve overall survival in a Phase III lung cancer trial. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.